Program
Liraglutide
Also written as “liraglutide”, “insulin degludec/liraglutide” and “Insulin degludec/liraglutide”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Diabetes Mellitus · Diabetes Mellitus, Type 1 · Osteoarthritis, Knee, led by 10 companies.
Drug pageLiraglutide: every studyMany companies study it; this page follows only the 109 they lead. All 336 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordiskits history only | 972 open or running | phase 4since Jul 22, 2013 | Sep 8, 2005 | Dec 13, 2026phase 1 · NCT07225816 |
| 4Moving Biotechits history only | 20 open or running | phase 2since Sep 24, 2025 | Jun 7, 2022 | none ahead |
| Eli Lillyits history only | 20 open or running | phase 4since Feb 24, 2014 | May 31, 2013 | none ahead |
| Tonghua Dongbao Pharmaceuticalits history only | 22 open or running | phase 3since Aug 14, 2024 | Jun 2, 2024 | none ahead |
| Biolingusits history only | 11 open or running | phase 2since Feb 16, 2022 | Feb 16, 2022 | none ahead |
| Cinnagenits history only | 10 open or running | phase 3since Jan 29, 2018 | Jan 29, 2018 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Sep 17, 2010 | Sep 17, 2010 | none ahead |
| Merckits history only | 10 open or running | phase 1since Jun 13, 2011 | Jun 13, 2011 | none ahead |
| Pfizerits history only | 10 open or running | phase 1since Feb 1, 2017 | Feb 1, 2017 | none ahead |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Aug 24, 2021 | Aug 24, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 42 studies since Jan 16, 2012.
- Sep 20, 20162 phase 3 studiesNovo Nordisk · NCT02911948, NCT02918279
- Nov 10, 20163 phase 3 studiesNovo Nordisk · NCT02963935, NCT02963922, NCT02964247
- Feb 1, 2017Pfizer’s first study: phase 1 study in ObesityNew to PfizerPfizer · NCT03041792 · 61 enrolled · United States
- May 24, 20172 phase 3 studies in Diabetes MellitusNovo Nordisk · NCT03175120, NCT03172494
- Sep 19, 2017Phase 1 study in Diabetes MellitusNovo Nordisk · NCT03292185 · 24 enrolled · China
- Jan 29, 2018Cinnagen’s first study: phase 3 study in Diabetes Mellitus, Type 2New to CinnagenCinnagen · NCT03421119 · 300 enrolled
- Feb 26, 2021Phase 3 study in ObesityNovo Nordisk · NCT04775082 · 82 enrolled · United States, Belgium, India and more
- Aug 24, 2021Sino Biopharmaceutical’s first study: phase 1 study in Diabetes Mellitus, Type 2New to Sino BiopharmaceuticalSino Biopharmaceutical · NCT05029076 · 28 enrolled · China
- Feb 16, 2022Biolingus’s first study: phase 2 study in Diabetes Mellitus, Type 2New to BiolingusBiolingus · NCT05268237 · 15 planned · Hong Kong
- Jun 7, 20224Moving Biotech’s first study: phase 1 study in Osteoarthritis, KneeNew to 4Moving Biotech4Moving Biotech · NCT05419856 · 34 enrolled · Belgium
- Jun 2, 2024Tonghua Dongbao Pharmaceutical’s first study: phase 1 study in HealthyNew to Tonghua Dongbao PharmaceuticalTonghua Dongbao Pharmaceutical · NCT06449703 · 44 planned · China
- Aug 14, 2024Phase 3 study in Diabetes Mellitus, Type 2Tonghua Dongbao Pharmaceutical · NCT06559722 · 510 planned
- Sep 24, 2025Phase 2 study in Osteoarthritis, Knee4Moving Biotech · NCT07225829 · 130 enrolled · United States, Canada, Denmark and more
- Nov 5, 2025Phase 1 study in ObesityNovo Nordisk · NCT07225816 · 71 planned · United States
Ahead
- Dec 13, 2026Primary completion: phase 1 study in ObesityNovo Nordisk · NCT07225816
TargetBeta
“Glucagon-like peptide 1 receptor agonist”ChEMBL 37, by rule
Other programs on GLP1R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Semaglutiderule | Novo Nordisk | phase 4 | 170 |
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| dulaglutiderule | Eli Lilly | phase 4 | 47 |
| orforglipronrule | Eli Lilly | phase 3 | 50 |
| zenagamtide | Novo Nordisk | phase 3 | 36 |
| survodutide | Boehringer Ingelheim | phase 3 | 35 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| mazdutiderule | Innovent Biologics | phase 3 | 27 |
| bofanglutiderule | Gan & Lee Pharmaceuticals | phase 3 | 25 |
| berobenatide | Pfizer | phase 3 | 23 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| Safiglipron | Jiangsu HengRui Medicine | phase 3 | 19 |
Studies
The newest 60 of 109 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07225816Obesity · United States | 1 | Recruiting | Novo Nordisk | Dec 13, 2026 | 71 |
| NCT07225829Osteoarthritis, Knee · United States, Canada, Denmark and more | 2 | Completed | 4Moving Biotech | Aug 31, 2026 | 130 |
| NCT06559722Diabetes Mellitus, Type 2 | 3 | Not yet recruiting | Tonghua Dongbao Pharmaceutical | Oct 2025 | 510 |
| NCT06449703Healthy · China | 1 | Recruiting | Tonghua Dongbao Pharmaceutical | Jun 16, 2024 | 44 |
| NCT05419856Osteoarthritis, Knee · Belgium | 1 | Completed | 4Moving Biotech | Oct 31, 2023 | 34 |
| NCT05268237Diabetes Mellitus, Type 2 · Hong Kong | 2 | Recruiting | Biolingus | Dec 2025 | 15 |
| NCT05029076Diabetes Mellitus, Type 2 · China | 1 | Completed | Sino Biopharmaceutical | Jun 1, 2019 | 28 |
| NCT04775082Obesity · United States, Belgium, India and more | 3 | Active, not recruiting | Novo Nordisk | Aug 1, 2023 | 82 |
| NCT03421119Diabetes Mellitus, Type 2 | 3 | UNKNOWN | Cinnagen | Dec 1, 2019 | 300 |
| NCT03292185Diabetes Mellitus · China | 1 | Completed | Novo Nordisk | Jan 2, 2018 | 24 |
| NCT03175120Diabetes Mellitus · China, Hong Kong | 3 | Completed | Novo Nordisk | Mar 5, 2019 | 453 |
| NCT03172494Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | Jun 14, 2019 | 720 |
| NCT03041792Obesity · United States | 1 | Completed | Pfizer | Jan 16, 2018 | 61 |
| NCT02964247Diabetes Mellitus · United States, Brazil, India and more | 3 | Completed | Novo Nordisk | May 4, 2018 | 303 |
| NCT02963935Nutrition Disorders · United States | 3 | Completed | Novo Nordisk | May 23, 2018 | 282 |
| NCT02963922Nutrition Disorders · United States, Canada, Germany and more | 3 | Completed | Novo Nordisk | Sep 10, 2018 | 396 |
| NCT02918279Nutrition Disorders · United States, Belgium, Mexico and more | 3 | Completed | Novo Nordisk | Feb 14, 2019 | 251 |
| NCT02911948Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 17, 2017 | 210 |
| NCT02773368Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Sep 26, 2017 | 420 |
| NCT02730377Diabetes Mellitus · United States, Canada, Colombia and more | 4 | Completed | Novo Nordisk | Aug 5, 2019 | 1,991 |
| NCT02717858Nutrition Disorders · Denmark | 1 | Completed | Novo Nordisk | Feb 27, 2017 | 52 |
| NCT02696148Nutrition Disorders · United States | 1 | Completed | Novo Nordisk | Apr 13, 2017 | 24 |
| NCT02607306Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Dec 15, 2017 | 819 |
| NCT02527200Nutrition Disorders · United States, Australia, Canada and more | 3 | Completed | Novo Nordisk | Nov 4, 2020 | 56 |
| NCT02505334Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | May 2, 2017 | 635 |
| NCT02501161Diabetes Mellitus · United States, Argentina, Brazil and more | 3 | Completed | Novo Nordisk | Oct 3, 2018 | 1,012 |
| NCT02443155Diabetes Mellitus · United States, Austria, Belgium and more | 2 | Completed | Novo Nordisk | Aug 31, 2018 | 308 |
| NCT02420262Diabetes Mellitus · United States, Argentina, Czechia and more | 3 | Completed | Novo Nordisk | Oct 5, 2016 | 506 |
| NCT02298192Diabetes Mellitus · United States, Austria, Bulgaria and more | 3 | Completed | Novo Nordisk | Dec 23, 2015 | 420 |
| NCT02207348Nutrition Disorders · Germany | 1 | Completed | Novo Nordisk | Sep 2014 | 24 |
| NCT02100475Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Apr 2015 | 31 |
| NCT02098395Diabetes Mellitus · United States, Austria, Belgium and more | 3 | Completed | Novo Nordisk | Apr 2015 | 835 |
| NCT02072096Diabetes Mellitus, Type 2 · United States, Austria, Germany and more | 4 | Terminated | Eli Lilly | Oct 2015 | 192 |
| NCT02008682Diabetes Mellitus · China | 4 | Completed | Novo Nordisk | Nov 2014 | 368 |
| NCT01973231Diabetes Mellitus · Czech Republic, Finland, France and more | 4 | Completed | Novo Nordisk | Nov 2014 | 404 |
| NCT01952145Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Nov 4, 2014 | 557 |
| NCT01916174Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | Nov 2013 | 50 |
| NCT01917656Diabetes Mellitus · Algeria, India, Israel and more | 4 | Completed | Novo Nordisk | Sep 1, 2014 | 343 |
| NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more | 4 | Completed | Novo Nordisk | Jun 15, 2015 | 407 |
| NCT01870297Diabetes Mellitus, Type 2 · United States | 1 | Completed | Eli Lilly | Dec 2014 | 72 |
| NCT01836523Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Novo Nordisk | Jun 2015 | 1,398 |
| NCT01789086Nutrition Disorders · Germany | 1 | Completed | Novo Nordisk | May 2014 | 21 |
| NCT01620489Diabetes Mellitus · United States, France, Poland and more | 3 | Completed | Novo Nordisk | Aug 20, 2013 | 279 |
| NCT01620476Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2004 | 24 |
| NCT01620463Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2003 | 32 |
| NCT01617434Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Novo Nordisk | Oct 2013 | 451 |
| NCT01615978Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2004 | 15 |
| NCT01572740Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 1, 2012 | 257 |
| NCT01557166Nutrition Disorders · United States, Canada | 3 | Completed | Novo Nordisk | Jun 1, 2013 | 359 |
| NCT01541215Diabetes Mellitus · United States, Australia, Austria and more | 3 | Completed | Novo Nordisk | Nov 15, 2017 | 135 |
| NCT01536665Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Aug 2012 | 45 |
| NCT01517568Diabetes Mellitus · Netherlands | 1 | Completed | Novo Nordisk | Dec 2006 | 7 |
| NCT01517555Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | May 2007 | 18 |
| NCT01516255Diabetes Mellitus · United States | 1 | Completed | Novo Nordisk | Nov 2006 | 64 |
| NCT01515592Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Apr 2006 | 24 |
| NCT01515579Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Jun 2006 | 22 |
| NCT01515553Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Apr 2007 | 22 |
| NCT01518166Diabetes Mellitus · Sweden | 1 | Completed | Novo Nordisk | Apr 2007 | 70 |
| NCT01514487Diabetes Mellitus · Australia | 1 | Completed | Novo Nordisk | Mar 30, 2005 | 24 |
| NCT01513525Diabetes Mellitus · Germany | 1 | Completed | Novo Nordisk | May 2007 | 21 |
How it is read
Names in the registry
- “liraglutide”, 114 entries
- “insulin degludec/liraglutide”, 11 entries
- “Liraglutide”, 10 entries
- “Insulin degludec/liraglutide”, 3 entries
- “NN9924 (oral)”, 2 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 75 studies
- Obesity, 18 studies
- Diabetes Mellitus, 14 studies
- Diabetes Mellitus, Type 1, 5 studies
- Osteoarthritis, Knee, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.